New 24-week clinical study strengthens the evidence of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
New 24-week clinical study strengthens the evidence of the therapeutic value of Zubsolv® for maintenance treatment of opioid dependence

Uppsala, Sweden – April 22, 2015 - Orexo AB today announced data from a 24-week clinical trial assessing the long-term safety and efficacy of Zubsolv® (buprenorphine/naloxone) sublingual tablet (CIII) for the maintenance treatment of opioid dependence. The results establish that Zubsolv is effective, well tolerated and demonstrated a safety profile consistent with the product labeling for sublingual buprenorphine products. In addition less than 1% of the patients exited the study due to treatment failure, which further underpins the medical value of Zubsolv. The results also demonstrated an increase of 15% in employment by the patients participating in the study, which further strengthen the evidence of the value of effective treatment of opioid dependence for the society. “This study reinforces and further highlights the safety and effectiveness of Zubsolv. Over the course of six months, the safety profile of Zubsolv was consistent with previous buprenorphine studies and patient symptoms continued to improve. In addition, we were able to observe the benefits of long-term treatment with Zubsolv on work productivity. As patients continued on their path to recovery, they experienced positive gains for employment status, hours of work missed, number of hours patients were able to work, productivity, and impairment of daily activities”, said Michael Sumner, Chief Medical Officer of Orexo. Benefits of long-term treatment for patients on their journey to recovery The primary objective of study OX219-008 was to assess the safety and tolerability of Zubsolv after an additional 24 weeks of treatment. The results from Study OX219-008, a multi-center, open-label, 24-week, follow-up study (N=665), establish that Zubsolv is well tolerated and effective for opioid dependent patients following six months of treatment. The safety profile was consistent with the product labeling for sublingual buprenorphine products. The most common AE was constipation (2.9%) and no individual events were reported in ≥5% of patients. There was one serious adverse event (SAE) that was considered treatment-related (depression that started on Day 19 and ceased on Day 27) and 6 patients discontinued the study with AEs that were considered by the investigator to be possibly related to treatment. Retention rates at Week 24 (end of study) were consistent with previous long -term clinical trials with buprenorphine. The retention rates at Weeks 4, 8, 12, 16, 20, and 24 (EOS) were 84.7%, 72.6%, 63.9%, 57.6%, 50.1%, and 43.9%, respectively. Opioid cravings were assessed on a 100 point VAS where 0 represented “no cravings” and 100 represented “the most intensive craving” the patient had ever had. Craving scores continued to improve during the extension study. At baseline of the parent studies before treatment was initiated, the mean opioid craving score was 70.8 and, by Week 24, the mean score had been improved to 10.9 in patients who completed the study. Health Economic Outcomes were assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem assessment (WPAI:SHP). The WPAI:SHP assessed 7 items related to work productivity and impairment associated with opioid dependence. By the end of the study in week 24, 15% more patients were currently employed as compared to the parent study baseline. In addition, patients reported missing 4.8 fewer hours of work per week on average due to their opioid dependence. Mean hours actually worked per week increased by 4.6 hours per week from baseline. Patients also reported improvements in the degree to which their opioid dependence affected their productivity and daily activities. Study OX219-008 was an extension of the ISTART (Study 006) and Study 007. Results from both of the parent studies have previously been released and can be found under the following link (http://www.orexo.com/en/Investor-Relations/Press -releases/?guid=899375). The ISTART study showed Zubsolv was as effective as Suboxone® Film and more than 70 percent preferred Zubsolv after being exposed to both Zubsolv and Suboxone Film. “The results of this extension study represent another addition to the already robust evidence base supporting Zubsolv as an effective and well tolerated maintenance treatment for patients struggling with opioid dependence. Zubsolv treatment supports opioid addicted patients in gaining control over their life and improves their ability to function in society, as evidenced by the higher employment rates at the end of the observation period concurrent with the demonstrated reduction in opioid cravings. Orexo’s investments in this follow-up study, and in planned future studies, demonstrate our continued commitment to advancing the treatment of opioid dependence for the patients suffering from this disease and providing effective and well tolerated therapies for physicians who treat them”, said Nikolaj Sørensen, Chief Executive Officer of Orexo. For further information, please contact: Nikolaj Sørensen, President and CEO Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com About Study OX219-008 Study OX219-008 was a multi-center, open-label, extension study in opioid dependent patients who had completed studies OX219-006 (ISTART) or OX219-007 to assess safety and efficacy for maintenance treatment of opioid dependence with Zubsolv. The primary objective was to assess the safety and tolerability of Zubsolv. Secondary objectives included retention in treatment, treatment effect on opioid withdrawal symptoms and opioid cravings, quality of life (QoL) and health economic outcomes (HEOs). Six hundred and sixty five patients entered the extension study (475 from the ISTART trial, 190 from Study 007). The total study period for each patient was up to approximately 24 weeks from the Day 1 visit to the Week 24 (end of study [EOS]) visit. All patients included in this extension study had previously received at least 22 days of buprenorphine therapy in the parent studies. No treatment adjuncts were mandated during the study (e.g. counseling, psychosocial support, participation in 12‑step programs). Study 008 included 7 treatment visits where the first visit was the same day as the last study day in the parent studies (ISTART and OX219 -007) with follow-up study visits every 4 weeks. Patients were maintained on the same dose of Zubsolv used in the previous studies. Patients who received Suboxone® Film on day 22 in the ISTART trial were switched to a corresponding dose of Zubsolv on Day 1. Zubsolv was individually titrated between 5.7/1.4 mg and 17.1/4.2 mg to a dose that relieved cravings and opioid withdrawal symptoms with minimal side effects. Dose adjustments were performed throughout the study as needed. About the ISTART Trial The ISTART Trial was a randomized, non-inferiority, multicenter study to assess early treatment efficacy of Zubsolv tablet versus Suboxone Film and to explore switching between treatments. The primary endpoints were retention in treatment at Day 15 and Day 3. Secondary efficacy assessments included scores on the COWS and SOWS, and opioid cravings VAS, CGI and PGI improvement from baseline, and switching between Zubsolv tablet and Suboxone Film. Seven hundred and fifty eight opioid dependent adult subjects were randomized. On days 1 and 2, patients received a blinded, fixed dose of Zubsolv (5.7/1.4 mg and 5.7/1.4 or 11.4/2.8 mg, respectively) or generic buprenorphine monotherapy (8 mg and 8 or 16 mg, respectively). On Day 3, the patients on generic buprenorphine were switched to Suboxone Film and patients in the Zubsolv tablet arm continued to receive Zubsolv. Stabilization doses were titrated to a maximum daily dose of 17.1/4.2 mg and 24/6 mg for Zubsolv tablet and Suboxone Film, respectively, based upon clinical symptoms. About Zubsolv Zubsolv (buprenorphine/naloxone) sublingual tablet (CIII) was approved by the U.S. Food and Drug Administration (FDA) on July 3, 2013, for maintenance treatment of opioid dependence and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. Treatment should be initiated under the direction of physicians who are certified under the Drug Addiction Treatment Act of 2000, and who have been assigned a unique identification number (“X” number). Zubsolv sublingual tablets can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient’s level of stability is essential. Liver function tests should be monitored before and during treatment. Children who take Zubsolv sublingual tablets can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Zubsolv sublingual tablets should be kept out of the sight and reach of children. Adverse events commonly observed with the sublingual administration of buprenorphine/ naloxone sublingual tablets during clinical trials and post -marketing experience are headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain and peripheral edema. Further information on Zubsolv can be found at www.zubsolv.com. Suboxone is a registered trademark of Reckitt Benckiser Healthcare (UK) Ltd. About Orexo Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D focuses on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden. www.orexo.com Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 9:00 am CET on April 22, 2015.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 44

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 74

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 165

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 34

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 159

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 57

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 42

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Swinerton Strengthens Leadership in Design-Build Initiatives

Updated Category News Views 250

Swinerton Welcomes Jason Bone as New Design-Build Leader In an exciting development, Swinerton Incorporated has bolstered its design-build leadership by appointing Jason Bone as the Director of National Design-Build. With this strategic move, the company reaffirms its dedication to providing exceptional client experiences while adapting to the evolving demands of the...

Continue Reading
PayPoint plc Announces PDMR Shareholding Updates

Updated Category News Views 144

PayPoint plc PDMR Share Acquisitions The company, PayPoint plc, recently shared exciting news regarding the shareholdings of its key executives, known as Persons Discharging Managerial Responsibilities (PDMRs). These PDMRs are significant players in the company, including its Executive Directors, and they participate in the Share Incentive Plan (SIP) designed to encourage...

Continue Reading
UMH Properties Announces First Quarter 2025 Financial Insights

Updated Category News Views 349

UMH Properties Reports Strong First Quarter Results for 2025 UMH Properties, Inc. (NYSE: UMH) recently revealed its financial results for the first quarter of 2025, showcasing encouraging growth and improvement in various operational metrics. The company reported a total income of $61.2 million for the quarter ending March 31, 2025, reflecting a 6% increase compared to...

Continue Reading
Netcompany Group Launches Share Buyback to Enhance Value

Updated Category News Views 245

Share Buyback Program Update from Netcompany Group Company announcement No. 20/2025 1 September 2025 On 14 August 2025, Netcompany Group A/S announced the initiation of a share buyback program of up to DKK 500 million, aiming to repurchase a total of 3,700,000 shares. This strategic move is designed to adjust the company’s capital structure while also fulfilling...

Continue Reading
Marex Group Investors: Join the Securities Fraud Class Action

Updated Category News Views 190

Recent Class Action Notice for Marex Group plc Investors In a significant announcement, a class action lawsuit has been filed that could impact many investors in Marex Group plc (NASDAQ: MRX). This legal action arises from reports that raise serious allegations regarding the company's financial reporting practices. For those who bought Marex shares, this is a crucial time...

Continue Reading